These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38299675)

  • 41. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions.
    Liu WL; Lin YH; Xiao H; Xing S; Chen H; Chi PD; Zhang G
    J Virol; 2014 Jun; 88(12):6660-71. PubMed ID: 24696473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
    Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
    Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.
    Yang L; Hakoda M; Iwabuchi K; Takeda T; Koike T; Kamatani N; Takada K
    J Virol; 2004 Sep; 78(18):9918-23. PubMed ID: 15331725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
    Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.
    Chen Y; Fachko DN; Ivanov NS; Skalsky RL
    mSphere; 2021 Apr; 6(2):. PubMed ID: 33853871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
    Guinness ME; Kenney JL; Reiss M; Lacy J
    Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
    Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
    Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients.
    Sivaraman P; Lye WC
    Biomed Pharmacother; 2001 Sep; 55(7):366-8. PubMed ID: 11669498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis.
    Mongini PK; Jackson AE; Tolani S; Fattah RJ; Inman JK
    J Immunol; 2003 Nov; 171(10):5244-54. PubMed ID: 14607925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation.
    Price AM; Luftig MA
    Adv Virus Res; 2014; 88():279-313. PubMed ID: 24373315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epstein-Barr Virus- (EBV-) Immortalized Lymphoblastoid Cell Lines (LCLs) Express High Level of CD23 but Low CD27 to Support Their Growth.
    Yap HY; Siow TS; Chow SK; Teow SY
    Adv Virol; 2019; 2019():6464521. PubMed ID: 31049064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation.
    Chou YC; Lin SJ; Lu J; Yeh TH; Chen CL; Weng PL; Lin JH; Yao M; Tsai CH
    Blood; 2011 Aug; 118(5):1340-9. PubMed ID: 21659546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.